GLP-1 Programs  ·  Physician-Governed

Your GLP-1 program, run by Lillia.

A hybrid program for obesity and Type 2 diabetes. Your clinicians prescribe and govern; Lillia runs the coaching, monitoring and follow-up around them, configured to how your clinic already works. Fewer patients fall off treatment, and every outcome is documented and reportable.

GlobalPresence across markets
50,000+Patients supported
10+Chronic conditions

How the partnership works

Your clinicians prescribe and govern. Lillia runs the program around them.

Your physicians hold every clinical decision. The patient app and your care portal are two faces of one platform, on a shared record, and the agents run the day to day. Switch sides to see it from each seat.

One message on the phone. The orchestrator routes it to every agent working on it. Hover any message, or any agent.

Orchestrator
LilliaHealth companionP
Suggest some good protein powder brands while I'm taking Mounjaro.
Since you're taking Mounjaro, it's important to talk to your doctor first, so it won't interfere with your medication. Once your doctor approves, I'll help you choose a healthy one.AI-generated
Yes, my doctor suggested protein powder. I'm pre-diabetic, so choose accordingly.
Then look for low sugar and carbs, at least 20 to 25 g of protein, and whey isolate, which is usually lower in carbs.AI-generated
You are now chatting with your care team.
Due to Ozempic I have low appetite and don't feel like eating. Could you suggest protein, omega and fibre supplements?
Reduced appetite is a common effect of Ozempic, and many people notice they eat less. Before adding supplements, try to meet your nutrition needs through food by choosing small, protein-rich meals and staying well hydrated. If you're unable to eat enough protein, a protein supplement may be helpful. Fiber supplements may also be useful if you're not getting enough fiber from your diet or if constipation becomes an issue. Omega-3 supplements are generally only needed if you don't regularly eat oily fish or if your doctor has specifically recommended them. Try to make these changes in your diet, and log your meals daily on the app so that I can review it. At your next appointment, we can discuss whether any supplements are appropriate based on your diet, weight, and overall health.
I have a bad stomachache. It's unbearable.
I'm sorry you're feeling this. Because it is severe, please contact your doctor or go to the nearest hospital immediately. Only a professional can find the cause and give the right care.AI-generated
Escalated to your care team, with the transcript
Suggest me some good protein powder brands.
I can't recommend particular brands, but I can help you choose the best product yourself. On the label, check: sugar 0 to 2 g per serving, protein at least 20 g, and a short ingredient list.AI-generated
Why can't you choose a brand?
My goal is to help you make choices you can repeat anywhere. Brands change; the skill to read a label lasts.AI-generated
Breakfast
Breakfast 8:10 AM
Took Glyciphage SR 1000 after this, did 4,800 steps today, and my fasting glucose was 132 this morning. What should I focus on?
8:13 AM
Thanks for the update. Our agents worked together on this.
NutritionBreakfast logged. Balanced and high in protein, good for steady glucose.
ActivityFasting glucose is a little high. A 10 to 15 minute walk after your next meal helps.
Diabetologist132 mg/dL is slightly above target. Keep monitoring the pattern.
MedicationGlyciphage SR 1000 logged. Adherence on track.
Next best stepAdd a short walk, keep meals balanced, and monitor your fasting readings.
8:14 AMAI-generated
+ Type a message...
1
Nutrition agent
Reads the logged meal, coaches the diet and builds the meal plans.
3
Diabetologist agent
Reads the number against target and watches the pattern.
2
Exercise agent
Turns steps and activity into the next best action.
4
Medication agent
Tracks adherence, and flags what your physician should see.
Safety guardrails
Defers to the physician, refuses brand endorsements, and escalates red flags.
Human care team
A named expert steps into the same thread when a person is needed.

The portal runs the program in the background. Pick a view.

portal.lilliacare.ai
Agent registry, including a GLP-1 Reminder Agent Call logs with human escalations and transcripts Outreach dashboard with call outcomes Consultations bookings

A registry of voice agents, including a GLP-1 Reminder Agent for adherence and side-effect reminders, plugged into the GLP-1 journey.

AI assisted care plans

Drafted by an AI assistant, then reviewed and approved by the practitioner before anything reaches the patient.

Clinician governed

Clinical decisions stay with the treating physician, and anything flagged routes to a named human immediately.

Recorded and auditable

Every agent interaction and call is logged, reviewable and reportable, so the work is provable to any payer.

Why the outcomes hold up

The same platform is a measurement engine.

Everything the app and your care team capture is written to one shared record that syncs with your EMR or EHR, so your clinicians and ours always work from the same data.

Structured clinical journeys

Every patient follows a defined 12-month pathway with set consultations and checkpoints, so outcomes stay comparable across a cohort.

Measured at every step

Labs, smart-scale and CGM data, and structured check-ins all feed the one shared record.

Machine learning that predicts trajectory

Our published models forecast glucose and HbA1c from adherence data, flagging who needs attention before results slip. Published in ADA 2026 ↗

The programs

Two programs: Obesity and Type 2 diabetes.

The figures below are Lillia's recommended targets, built from the ADA 2026 Standards of Care and our published research. This is our version of the program; we adapt the targets, the journey and the cadence to your clinic's protocols.

Obesity

GLP-1 powered obesity management, tracked by smart-scale body composition, not weight alone.

Our recommended targets based on ADA 2026, adapted to your protocols

Smart scale · Muscle-sparing focus · Relapse prevention

12 to 15%
weight-loss target for patients starting at BMI 30 or above
10 to 12%
for patients at BMI 27 to 29.9 with a comorbidity
2 to 3 in
of inch loss off the waistline
>70%
of members targeted to exceed 5% weight loss

Measurable improvement in associated comorbidities: blood pressure, lipids and metabolic health.

Type 2 Diabetes

GLP-1 powered Type 2 diabetes management, with continuous glucose monitoring guiding safe titration.

Our recommended targets based on ADA 2026, adapted to your protocols

CGM guided · Hypoglycemia protection · Digital-twin insight

1 to 1.5
%-point drop in average HbA1c
2 to 2.5
%-point drop for patients starting above 9%
+15 to 20
%-point improvement in time-in-range
5 to 10%
associated weight loss

Measurable improvement in associated comorbidities: blood pressure, lipids and cardiovascular risk.

How it runs

Side effects, adherence and monitoring.

Starting the medicine is easy. Keeping patients on it safely is the real work.

01

Side-effect management

We anticipate and coach patients through nausea and other GI effects from the first dose, the single biggest reason people stop GLP-1 in the early weeks.

02

Adherence support

Injection reminders, weekly check-ins and a coach on call keep patients on dose and on track between clinic visits.

03

Symptom and safety tracking

Symptoms and glucose are tracked continuously, and anything concerning is routed through a structured escalation matrix to the right responder.

The 12-month journey

Two views of the same structured program: the day-by-day journey, and the team that delivers it.

1

Across the first week: history and eligibility, app onboarding, baseline labs, devices dispatched, and your physician's prescription.

Health coachPhysicianBaseline labs
2

Smart scale, and CGM for diabetes, set up with guided support. The journey clock starts here.

Health coachSmart scaleCGM
3

First injection with a coach on video, the full multidisciplinary consult, and the first diet and exercise plans.

PhysicianHealth coachNutritionistExercise coach
4

Nutritionist reviews scale and vitals against food and activity logs; the plan is updated.

Nutritionist
5

Multidisciplinary review; your physician assesses response and side effects and adjusts the dose.

PhysicianNutritionistHealth coach
6

Repeat bloods (HbA1c, lipid profile, liver profile, etc.) collected to measure the response objectively.

Follow-up labs
7

Progress review, prescription confirmed, and a formal transition into the sustenance phase.

Full care team
8

Consultation frequency tapers while monitoring continues. Repeat lab tests as indicated, quarterly and at the end of the program, with physician-led dose titration through to a planned off-ramp.

Care teamAI monitoring

Weekly AI check-ins and injection reminders run continuously between these milestones, catching barriers and new symptoms early, before they turn into drop-offs.

21 consultations in the first 90 days

One-to-one, plus weekly check-ins and continuous device monitoring. Every touchpoint is scheduled, not left to chance.

Then through the sustenance phase (Months 4 to 12): monthly consultations with experts, with weekly check-ins by the health coach.

Physician
5 consults
Owns eligibility, prescription and every dose-titration decision.
Health coach
5 + weekly
Adherence, motivation and side-effect first response.
Nutritionist
6 consults
Condition-specific nutrition, individualized and reviewed monthly.
Exercise coach
5 consults
Activity that protects muscle and improves metabolic health.
AI agents
24 / 7
Reminders, symptom and safety surveillance, and trajectory prediction.
Devices & monitoring
Continuous
Smart scale and CGM feed the record and flag issues in real time.

Safety & governance

Set with your clinical team.

Escalation thresholds, red-flag routing and who gets called are co-defined with your clinicians. The clinical essentials:

01Your physician owns prescribing and every dose change
Weight plateau or disengagementHealth-coach outreach; nutrition and exercise plan review; physician review of dose at the next or an earlier consult.
Uncontrolled GI side effects (nausea, vomiting, severe constipation)Coach-led dietary mitigation first; slower dose titration considered; physician review if symptoms persist or are severe.
Suspected pancreatitis, biliary disease, or bowel obstructionSame-day physician escalation; discontinue therapy pending evaluation if pancreatitis is suspected.
New vision changesPrompt evaluation: rare reports of NAION with GLP-1 therapy warrant monitoring, particularly in longer-duration diabetes.
Included
  • Adults over 18
  • Obesity: BMI ≥30, or ≥27 with an obesity-associated comorbidity
  • Type 2 diabetes: any duration
  • Owns a smartphone and is comfortable with digital tools
Excluded
  • Type 1 or gestational diabetes, or autoimmune-driven glycemic disease
  • Active malignancy, uncontrolled endocrine disorder, or acute illness (sepsis, pancreatitis, liver or kidney failure)
  • Recent myocardial infarction or acute heart failure
  • Pregnancy or trying to conceive (GLP-1 contraindicated; contraception counseling required)
  • Significant GI disorders such as gastroparesis
  • Personal or family history of medullary thyroid carcinoma or MEN 2
  • Unable or unwilling to use mobile health tools
04Safety reviewed monthly, then quarterly

On the numbers. Targets align to the ADA 2026 Standards of Care and reflect landmark trials: SURMOUNT-2 recorded 9.6 to 11.6% additional weight loss with Tirzepatide, and STEP 2 recorded 6.2% with Semaglutide 2.4 mg. They are design targets, measured against each cohort in delivery.

In-app education

Patients stay on therapy when they understand it.

A plain-language, physician-approved library unlocks step by step through the journey, turning the moments that usually cause drop-off into moments patients are ready for.

Understanding GLP-1 therapyHow to take your injectionManaging nausea & GI side effectsWhen to call us right awayStoring & traveling with your medicationYour off-ramp: tapering & long-term useFor caregivers & family Understanding GLP-1 therapyHow to take your injectionManaging nausea & GI side effectsWhen to call us right awayStoring & traveling with your medicationYour off-ramp: tapering & long-term useFor caregivers & family
High-protein, high-fiber nutritionMovement that protects muscleHunger control & relapse preventionReading your CGMRecognizing & treating hypoglycemiaLow-GI eating & meal timingSick-day basics High-protein, high-fiber nutritionMovement that protects muscleHunger control & relapse preventionReading your CGMRecognizing & treating hypoglycemiaLow-GI eating & meal timingSick-day basics
Core, every program Weight Diabetes

Our published research

Peer-reviewed in chronic care and diabetes.

Lillia's published research is in digital chronic-care and diabetes, in journals including the American Diabetes Association's Diabetes and Elsevier. We do not yet publish GLP-1 cohort outcomes; this is the measurement rigour we bring to the GLP-1 program.

8
peer-reviewed studies since 2021, spanning digital diabetes care, CGM outcomes and machine-learning prediction.
2026
ADA · Diabetes · 1956-P
Multimodal Machine Learning for Real-Time Glucose Prediction in Adults with Diabetes
Read ↗
2026
ADA · Diabetes · 2053-P
Estimating HbA1c Using Demographic & Behavioral Adherence Metrics
Read ↗
2025
Elsevier · DRCP
A CGM Program’s Effectiveness Across Indian City Tiers
Read ↗
2025
Int. J. Research in Medical Science
An Integrated Approach to Treating Diabetes: Modern Technologies with Homeopathy
Read ↗
2024
IJRMS · Paper
Integrated Model of Digital Health & Clinic Care Pathway in Indian T2DM
Read ↗
2022
ADA · Diabetes
Real-World Evidence of Digital Therapeutics for People with Type 2 Diabetes
Read ↗
2021
Elsevier · Paper
Patients’ & Healthcare Workers’ Experience with a Diabetes Self-Management App
Read ↗
2021
ADA · Diabetes
Generating Self-Reported Clinical & Lifestyle Data in Patients with T2DM
Read ↗
2026
ADA · Diabetes · 1956-P
Multimodal Machine Learning for Real-Time Glucose Prediction in Adults with Diabetes
Read ↗
2026
ADA · Diabetes · 2053-P
Estimating HbA1c Using Demographic & Behavioral Adherence Metrics
Read ↗
2025
Elsevier · DRCP
A CGM Program’s Effectiveness Across Indian City Tiers
Read ↗
2025
Int. J. Research in Medical Science
An Integrated Approach to Treating Diabetes: Modern Technologies with Homeopathy
Read ↗
2024
IJRMS · Paper
Integrated Model of Digital Health & Clinic Care Pathway in Indian T2DM
Read ↗
2022
ADA · Diabetes
Real-World Evidence of Digital Therapeutics for People with Type 2 Diabetes
Read ↗
2021
Elsevier · Paper
Patients’ & Healthcare Workers’ Experience with a Diabetes Self-Management App
Read ↗
2021
ADA · Diabetes
Generating Self-Reported Clinical & Lifestyle Data in Patients with T2DM
Read ↗

Hover to pause, and tap any card to open the abstract. Published under Lillia’s former name, Droobi.

Let's build it together

Let's design the GLP-1 program that fits your patients.

Tell us who you serve, whether a clinic network, an insured population, or a therapy you want to support, and we will shape the program, the targets and the reporting around it.